Over the past decade, the ability to target specific oncogenic drivers has transformed the treatment of advanced or metastatic non–small cell lung cancer (NSCLC).
Dr Jonathan Goldman, of UCLA Medical Center, discusses the range of mutations identified in NSCLC, including EGFR, ALK, KRAS G12C, MET, BRAF, and fusions including ROS1, RET, and NTRK.
Dr Goldman compares different options for gene testing and discusses how the utilization of tumor testing still varies greatly despite the availability of targeted therapies.
Finally, he explores the range of approved first-line therapies used to target commonly identified mutations.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: First-Line Treatment of Advanced/Metastatic NSCLC - Medscape - Jul 02, 2022.
Comments